Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on- …

Ligand Pharmaceuticals Reiterates FY25 Outlook - Update

While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and revenue guidance for fiscal 2025. For fiscal 2025, the company continues to project …

Suven Pharmaceuticals rebranded as Cohance Lifesciences

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences. The move according to the company represents more than just a name change as it marks an evolution into a specialized, technology-driven …

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here’s Why.

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that missed analysts’ expectations and disclosed narrower-than-expected access to its new non-opioid painkiller. Shares were down 13%, …

Why Apellis Pharmaceuticals Wilted on Wednesday

A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on …

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s …

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the ...

VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to …

Adial Pharmaceuticals raises $2.75M

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

– Total revenues of $898 million in 1Q25 – – Xywav® and Epidiolex® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 – – Completed submission of sNDA for Zepzelca® in 1L ES-SCLC – – Affirming 2025 revenue guidance; updating financial guidance …

Camber Pharmaceuticals Announces Addition of Eslicarbazepine Acetate Tablets

Camber Pharmaceuticals is excited to announce the addition of Eslicarbazepine Acetate Tablets to its portfolio. Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. Eslicarbazepine …